|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:ATCCode
|
L04AA29
|
|
gptkbp:blackBoxWarning
|
thrombosis
malignancy
serious infections
|
|
gptkbp:brand
|
gptkb:Xeljanz
Jakvinus
Tofacinix
|
|
gptkbp:CASNumber
|
540737-29-9
|
|
gptkbp:chemicalFormula
|
C16H20N6O
|
|
gptkbp:contraindication
|
active tuberculosis
serious infections
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:drugClass
|
immunosuppressant
disease-modifying antirheumatic drug (DMARD)
|
|
gptkbp:eliminationHalfLife
|
3 hours
|
|
gptkbp:firstApprovedCountry
|
gptkb:United_States
|
|
gptkbp:form
|
gptkb:tablet
extended-release tablet
|
|
gptkbp:genericAvailable
|
no (as of 2024)
|
|
gptkbp:genericName
|
gptkb:tofacitinib
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xeljanz
|
|
gptkbp:indication
|
gptkb:psoriatic_arthritis
ulcerative colitis
rheumatoid arthritis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
Janus kinase inhibitor
|
|
gptkbp:metabolism
|
liver (CYP3A4, CYP2C19)
|
|
gptkbp:molecularWeight
|
312.37 g/mol
|
|
gptkbp:patent
|
gptkb:Pfizer
|
|
gptkbp:pregnancyCategory
|
C (US)
not recommended in pregnancy
|
|
gptkbp:prescribes
|
adults
children (for some indications)
|
|
gptkbp:prescriptionStatus
|
Rx-only
|
|
gptkbp:riskFactor
|
increased risk of blood clots
increased risk of cancer
serious infections
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
headache
high blood pressure
infections
increased cholesterol
|
|
gptkbp:bfsParent
|
gptkb:tofacitinib
|
|
gptkbp:bfsLayer
|
8
|